Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2018

Pulliam Nicholas, Fang Fang, Ozes Ali R, Tang Jessica, Adewuyi Adeoluwa, Keer Harold, Lyons John, Baylin Stephen B, Matei Daniela, Nakshatri Harikrishna, Rassool Feyruz V, Miller Kathy D, Nephew Kenneth P

Abstract excerpt

Purpose: PARP inhibitors (PARPi) are primarily effective against BRCA1/2-mutated breast and ovarian cancers, but resistance due to reversion of mutated BRCA1/2 and other mechanisms is common. Based on previous reports demonstrating a functional role for DNMT1 in DNA repair and our previous studies demonstrating an ability of DNA methyltransferase inhibitor (DNMTi) to resensitize tumors to primary therapies, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclic AMP

Share to Cyclic AMP-Dependent Protein Kinases

Share to Phthalazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Reactive Oxygen Species

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29615458
DOI: 10.1158/1078-0432.CCR-18-0204
PMCID: PMC7003715

Genes

BRCA1
DNMT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.PMID 29615458Read ↗

A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerSemantic proximity Read ↗

Efficacy and Mechanism of the Combination of PARP and CDK4/6 Inhibitors in the Treatment of Triple-negative Breast CancerSemantic proximity Read ↗

The potential of PARP inhibitors in genetic breast and ovarian cancers.Semantic proximity Read ↗

Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentSemantic proximity Read ↗

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.Semantic proximity Read ↗

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsSemantic proximity Read ↗

Efficacy and Safety of BRCA-targeted Therapy (Polyadenosine Diphosphate-ribose Polymerase Inhibitors) in Treatment of BRCA-mutated Breast Cancer: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

PARP inhibition in breast cancer.Semantic proximity Read ↗

The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.Semantic proximity Read ↗

Advances in the use of PARP inhibitor therapy for breast cancerSemantic proximity Read ↗

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencingSemantic proximity Read ↗

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.